SOPHiA GENETICS S.A. (SOPH) vs Starling Oncology, Inc. (STLN)

A side-by-side comparison of SOPHiA GENETICS S.A. and Starling Oncology, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
SOPHiA GENETICS S.A. logo
SOPH
SOPHiA GENETICS S.A.
$619M
$7.38HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Starling Oncology, Inc. logo
STLN
Starling Oncology, Inc.
$658M
$6.58HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — SOPH vs STLN

growth of $100 · dividends reinvested · last 1y
SOPH +50.7% (+50.7%/yr)STLN +8.6% (+8.6%/yr)SOPH compounded faster over this window
80100120140160Start $100$151$109
SOPH STLN

SOPH vs STLN: by the numbers

  • •STLN is the larger company ($658M vs $619M market cap).
  • •Both run net losses; STLN's is the smaller (-6.18% vs -93.86% net margin).

Metrics side by side

Valuation

MetricSOPHSTLN
P/S ratio7.191.12
P/B ratio7.45N/A

Profitability

MetricSOPHSTLN
Gross margin66.63%15.69%
Operating margin-85.01%-4.44%
Net margin-93.86%-6.18%
ROE-97.31%N/A
ROIC-49.73%-31.32%

Growth (annualized)

MetricSOPHSTLN
Revenue CAGR (5Y)20.33%N/A
Total return CAGR (5Y)-13.62%N/A

Go deeper

Full SOPH analysisFull STLN analysisInteractive comparison tool

Dig into the metrics

SOPHiA GENETICS ROEStarling Oncology ROESOPHiA GENETICS operating marginStarling Oncology operating marginSOPHiA GENETICS revenue growthStarling Oncology revenue growthSOPHiA GENETICS free cash flowStarling Oncology free cash flow

SOPHiA GENETICS & Starling Oncology appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.